| Zhang, Qingyuan |
TQB2450-III-06, NCT04405505: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 3 | 332 | RoW | TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Triple Negative Breast Cancer | 07/22 | 07/22 | | |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 542 | RoW | TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/27 | 12/28 | | |
NCT05257395: A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer |
|
|
| Not yet recruiting | 3 | 372 | RoW | XZP-3287+ Letrozole/Anastrozole, Placebo + Letrozole/Anastrozole | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Breast Cancer | 12/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
OPTIMAL, NCT03315364: Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy |
|
|
| Active, not recruiting | 2/3 | 549 | Europe, RoW | Oral paclitaxel, Liporaxel®, Paclitaxel injection, Taxol® | Daehwa Pharmaceutical Co., Ltd. | Recurrent or Metastatic Breast Cancer | 02/24 | 12/25 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05860465: Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 2/3 | 254 | RoW | SPH4336 Tablets, SPH4336 Tablets Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | Locally Advanced or Metastatic Breast Cancer | 03/25 | 08/25 | | |
NCT04165993: Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer |
|
|
| Active, not recruiting | 2 | 68 | RoW | Concurrent chemotherapy and KN026, docetaxol, KN026 monotherapy, KN026, KN026 combination, KN046 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Metastatic Breast Cancer | 05/21 | 12/25 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT04927481: A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer |
|
|
| Terminated | 2 | 28 | RoW | Mitoxantrone Hydrochloride Liposome Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 01/23 | 01/23 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT04614740: The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 115 | RoW | VC004 | Jiangsu vcare pharmaceutical technology co., LTD | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 01/24 | 06/24 | | |
TQB2102-II-01, NCT06198751: A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer |
|
|
| Recruiting | 2 | 104 | RoW | 6.0 mg/kg of TQB2102 for injection, 7.5 mg/kg of TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Breast Cancer | 01/25 | 02/26 | | |
NCT06354114: A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 |
|
|
| Not yet recruiting | 2 | 80 | RoW | SYHX2011 | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Breast Cancer | 10/24 | 12/26 | | |
HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors |
|
|
| Active, not recruiting | 2 | 131 | RoW | HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU | Shanghai Henlius Biotech | Head and Neck Squamous Cell Carcinoma | 05/24 | 06/25 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT06601504: Study of HMPL-760 Puls R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL |
|
|
| Not yet recruiting | 2 | 60 | RoW | HMPL-760 planned dose 1, R-GemOx, Rituximab Injection, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride for Injection, HMPL-760 placebo planned dose 1, HMPL-760 planned dose 2, HMPL-760 placebo planned dose 2 | Hutchmed | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 05/26 | 11/26 | | |
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 42 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 06/26 | 06/28 | | |
TQB3702-II-02, NCT06566586: A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma |
|
|
| Recruiting | 2 | 80 | RoW | TQB3702 tablets+Chemotherapy regimen | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | B-cell Lymphoma | 03/26 | 12/27 | | |
NCT05872347: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases. |
|
|
| Recruiting | 2 | 52 | RoW | SPH4336 Tablets | Shanghai Pharmaceuticals Holding Co., Ltd | Breast Cancer Brain Metastases | 12/25 | 12/25 | | |
NCT06202261: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 154 | RoW | TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule, Fulvestrant injection, Capecitabine tablets, Vinorelbine tartrate injection, Eribulin mesylate injection, gemcitabine hydrochloride for injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies | 12/26 | 10/27 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 220 | RoW | Dose Escalation, Dose Expansion1, Dose Expansion2, phase II | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Advanced Malignant Solid Tumors | 05/28 | 12/28 | | |
NCT06679036: A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients |
|
|
| Not yet recruiting | 1/2 | 300 | RoW | HRS-2189, Fluvustat, HRS-8080, HRS-6209, HRS-1358 | Shandong Suncadia Medicine Co., Ltd. | Advanced Unresectable or Metastatic Breast Cancer | 10/26 | 12/26 | | |
NCT04980690: Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 228 | RoW | IBC0966 | SUNHO（China）BioPharmaceutical CO., Ltd. | Advanced Malignant Tumors | 12/24 | 12/25 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 1/2 | 300 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT04871347: The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor |
|
|
| Not yet recruiting | 1a/1b | 58 | RoW | TWP-101, Sytalizumab Injection | Shandong TheraWisdom Biopharma Co., Ltd. | Advanced Solid Tumor | 06/23 | 12/23 | | |
NCT03374007: Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma |
|
|
| Recruiting | 1 | 72 | RoW | Geptanolimab Injection 1mg/kg, Recombinant PD-1 humanized monoclonal antibody injection, Geptanolimab Injection, Geptanolimab Injection 3mg/kg, Geptanolimab Injection 10mg/kg, Geptanolimab Injection 1mg/kg, q2w*6, Geptanolimab Injection 3mg/kg, q2w*6, Geptanolimab Injection 10mg/kg, , q2w*6, Geptanolimab Injection 280mg, q3w, Geptanolimab Injection 3mg/kg, q2w | Genor Biopharma Co., Ltd. | Advanced Solid Tumor, Recurrent Solid Tumor, Lymphoma, Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma | 06/22 | 08/22 | | |
TWP-102-11, NCT05024305: Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies. |
|
|
| Recruiting | 1 | 81 | RoW | TWP-102 injection | Shandong TheraWisdom Biopharma Co., Ltd. | Advanced Malignancies | 12/22 | 06/23 | | |
NCT05103826: A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer |
|
|
| Terminated | 1 | 3 | RoW | SHR6390、Famitinib | Jiangsu HengRui Medicine Co., Ltd. | ER+ / HER2- Advanced Breast Cancer | 06/23 | 06/23 | | |
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SPH5030 tablets | Shanghai Pharmaceuticals Holding Co., Ltd | HER2-positive Advanced Solid Tumors | 12/24 | 12/24 | | |
BL-M17D1-101, NCT06503783: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 08/26 | 08/26 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
| Recruiting | 1 | 150 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT05851092: Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 60 | RoW | HRS-2189 Tablets | Shandong Suncadia Medicine Co., Ltd. | Advanced Malignant Tumor | 12/25 | 12/25 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
| ZHANG, YANQIAO |
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT06432296: Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody |
|
|
| Recruiting | 3 | 270 | RoW | M701, paracentesis | Wuhan YZY Biopharma Co., Ltd. | Malignant Ascites | 08/25 | 11/25 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor |
|
|
| Not yet recruiting | 2 | 138 | RoW | AK105, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MSI-H or dMMR Advanced Solid Tumors | 12/22 | 12/22 | | |
MRG002-002, NCT04837508: A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 86 | RoW | MRG002 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 12/22 | 08/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT06155383: Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. |
|
|
| Recruiting | 2 | 90 | RoW | Capecitabine, oxaliplatin, Disitamab Vedotin, RC48, Toripalimab, JS001 | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 01/25 | 12/27 | | |
NCT06512428: A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 138 | RoW | simmitinib plus irinotecan liposome, irinotecan liposome, irinotecan | Shanghai Runshi Pharmaceutical Technology Co., Ltd | Advanced Esophageal Squamous Cell Carcinoma | 01/26 | 01/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
NCT04838964: A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Recruiting | 2 | 80 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Biliary Tract Cancer | 10/24 | 11/24 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05024214: Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors |
|
|
| Recruiting | 1/2 | 170 | RoW | Lenvatinib + Envafolimab, Sunitinib | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma | 12/24 | 12/24 | | |
NCT05846867: Study of AK119 and AK 112 With or Without Chemotherapy for Colorectal Cancer Patients |
|
|
| Not yet recruiting | 1/2 | 72 | RoW | AK119, AK112, Oxaliplatin, Irinotecan, Calcium folinate, Fluorouracil | Akeso | Colorectal Cancer | 05/24 | 07/25 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
| Active, not recruiting | 1/2 | 206 | RoW | LM-302 Injection | LaNova Medicines Zhejiang Co., Ltd. | Advanced Solid Tumor | 03/25 | 06/25 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT05470933: A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors |
|
|
| Terminated | 1 | 7 | RoW | WJ01075 | Suzhou Junjing BioSciences Co., Ltd. | Advanced Solid Tumors | 04/23 | 04/23 | | |
NCT05554666: A Study of ASKG315 in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 56 | RoW | ASKG315 | AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/23 | 10/24 | | |
| Recruiting | 1 | 31 | US, RoW | AN4005-dose level 0, AN4005-dose level 1, AN4005-dose level 2, AN4005-dose level 3, AN4005-dose level 4, AN4005-food effect | Adlai Nortye Biopharma Co., Ltd. | Advanced Solid Tumor, Advanced Lymphoma | 08/25 | 12/25 | | |
| Recruiting | 1 | 250 | RoW | QLC1101 | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor | 05/26 | 04/27 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
NCT05277454: Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT |
|
|
| Recruiting | 1 | 113 | RoW | HMPL-653 | Hutchison Medipharma Limited | Advanced Malignant Solid Tumors, TGCT | 06/24 | 04/25 | | |
| Recruiting | 1 | 37 | RoW | ET0111 | Etern BioPharma (Shanghai) Co., Ltd | Advanced Solid Tumor | 12/24 | 05/25 | | |
| Recruiting | 1 | 50 | RoW | TR128 | Tarapeutics Science Inc. | Advanced Solid Tumor | 08/25 | 12/25 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Recruiting | 1 | 72 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 08/25 | 08/25 | | |
NCT05407909: To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 176 | RoW | SYHX2001 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced or Metastatic Solid Tumors | 01/26 | 01/26 | | |
| Yu, Yan yan |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 700 | RoW | HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin | Taizhou Hanzhong biomedical co. LTD | Nonsquamous Non-small Cell Lung Cancer | 09/22 | 09/23 | | |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases |
|
|
| Active, not recruiting | 2 | 63 | RoW | Almonertinib, Investigational Product | Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 06/24 | 07/24 | | |
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 99 | US, RoW | Sutetinib Maleate Capsule, Sutetinib | Teligene US | Non-small Cell Lung Cancer | 08/24 | 02/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib |
|
|
| Not yet recruiting | 2 | 54 | RoW | ABSK043 in combination with Firmonertinib | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer With EGFR Mutation | 06/27 | 06/28 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 164 | US, RoW | ABSK112, EGFR Exon20 inhibitor | Abbisko Therapeutics Co, Ltd | Non-Small Cell Lung Cancer | 03/27 | 03/28 | | |
NCT06235983: A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | LY3537982, Olomorasib | Eli Lilly and Company | Advanced Solid Tumors | 01/25 | 01/26 | | |
NCT02929290: Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC |
|
|
| Recruiting | 1 | 80 | RoW | BPI-9016M, No other name so far | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 11/24 | 11/24 | | |
NCT05789602: A Study of BPI-460372 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 82 | RoW | BPI-460372 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
| Chen, Gongyan |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
| Wang, Jingxuan |
| No trials found |
